Sangamo Therapeutics Inc (NASDAQ:SGMO) – Investment analysts at Wedbush dropped their Q1 2019 earnings per share estimates for Sangamo Therapeutics in a research note issued to investors on Monday, March 11th. Wedbush analyst L. Moussatos now anticipates that the biopharmaceutical company will earn ($0.16) per share for the quarter, down from their previous forecast of ($0.10). Wedbush has a “Hold” rating and a $10.00 price objective on the stock. Wedbush also issued estimates for Sangamo Therapeutics’ Q2 2019 earnings at ($0.16) EPS, Q3 2019 earnings at ($0.17) EPS, FY2019 earnings at ($0.64) EPS, FY2020 earnings at ($1.16) EPS, FY2021 earnings at ($1.40) EPS, FY2022 earnings at ($1.46) EPS and FY2023 earnings at ($1.52) EPS.
Other research analysts have also issued reports about the company. ValuEngine lowered Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 2nd. BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, November 28th. JPMorgan Chase & Co. lowered Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $35.00 to $11.00 in a report on Wednesday, November 14th. Finally, Zacks Investment Research lowered Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Sangamo Therapeutics presently has an average rating of “Hold” and a consensus target price of $16.40.
Shares of SGMO stock opened at $10.10 on Thursday. The company has a current ratio of 6.32, a quick ratio of 6.32 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $1.02 billion, a PE ratio of -14.43 and a beta of 2.84. Sangamo Therapeutics has a fifty-two week low of $6.26 and a fifty-two week high of $26.15.
In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the stock in a transaction that occurred on Monday, December 17th. The stock was sold at an average price of $11.44, for a total transaction of $57,200.00. Following the transaction, the chief financial officer now owns 12,250 shares in the company, valued at $140,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 20,000 shares of company stock worth $224,050 in the last quarter. 1.20% of the stock is currently owned by company insiders.
A number of hedge funds have recently modified their holdings of SGMO. BB Biotech AG purchased a new position in Sangamo Therapeutics during the fourth quarter worth approximately $15,498,000. Dimensional Fund Advisors LP boosted its position in Sangamo Therapeutics by 459.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,239,110 shares of the biopharmaceutical company’s stock worth $14,224,000 after purchasing an additional 1,017,573 shares in the last quarter. Credit Suisse AG boosted its position in Sangamo Therapeutics by 23.5% during the third quarter. Credit Suisse AG now owns 2,184,505 shares of the biopharmaceutical company’s stock worth $37,027,000 after purchasing an additional 415,764 shares in the last quarter. Tocqueville Asset Management L.P. boosted its position in Sangamo Therapeutics by 108.6% during the third quarter. Tocqueville Asset Management L.P. now owns 711,237 shares of the biopharmaceutical company’s stock worth $12,055,000 after purchasing an additional 370,297 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in Sangamo Therapeutics during the fourth quarter worth approximately $3,903,000. Institutional investors own 62.46% of the company’s stock.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Read More: What is Compound Interest?